Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
金曜日, 8 21

BeOne Medicines Ltd

ONCNASDAQ
Trade with Public
Trade with Public
$369.16
-7.70-2.04%
近くで: Aug 19, 5:00 PM EST
$374.94
-1.92-0.51%
プレマーケット: 7:41 AM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

BeOne Medicines Analyst Price Targets

Wall Street analyst price targets and consensus rating for BeOne Medicines (ONC).

Price Target Range — 7 Quarters

Analyst Consensus — 16 Analysts

2S.Buy
14Buy
Consensus RatingBuy# Analysts16Avg. Consensus PT$384Upside to Avg. PT+2.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 6, 2026TD CowenYaron WerberPT RaiseBuy$424→$454
Aug 6, 2026RBC CapitalLeonid TimashevPT CutOutperform$451→$450
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
TD Cowen Maintains Buy on BeOne Medicines, Raises Price Target to $454

TD Cowen analyst Yaron Werber maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $424 to $454.
Benzinga Newsdesk

PRO
RBC Capital Maintains Outperform on BeOne Medicines, Lowers Price Target to $450

RBC Capital analyst Leonid Timashev maintains BeOne Medicines (NASDAQ:ONC) with a Outperform and lowers the price target from $451 to $450.
Benzinga Newsdesk

PRO
Truist Securities Maintains Buy on BeOne Medicines, Raises Price Target to $418

Truist Securities analyst Gregory Renza maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $416 to $418.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on BeOne Medicines, Raises Price Target to $430

Guggenheim analyst Michael Schmitz maintains BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $420 to $430.
Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on BeOne Medicines, Raises Price Target to $405

Citizens analyst Reni J. Benjamin maintains BeOne Medicines (NASDAQ:ONC) with a Market Outperform and raises the price target from $396 to $405.
Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on BeOne Medicines, Raises Price Target to $425

JP Morgan analyst Jessica Fye maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $415 to $425.
Benzinga Newsdesk

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

市場データ提供元 Benzinga API

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved